183 related articles for article (PubMed ID: 20948683)
1. New therapies for recurrent glioblastomas.
Wen PY
F1000 Med Rep; 2009 Dec; 1():. PubMed ID: 20948683
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent high-grade gliomas.
Wen PY; Brandes AA
Curr Opin Neurol; 2009 Dec; 22(6):657-64. PubMed ID: 19770658
[TBL] [Abstract][Full Text] [Related]
3. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for malignant gliomas.
Iwamoto FM; Fine HA
Arch Neurol; 2010 Mar; 67(3):285-8. PubMed ID: 20212225
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bevacizumab in glioblastomas.
De Fazio S; Russo E; Ammendola M; Donato Di Paola E; De Sarro G
Curr Med Chem; 2012; 19(7):972-81. PubMed ID: 22214463
[TBL] [Abstract][Full Text] [Related]
6. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Zustovich F; Lombardi G; Pastorelli D; Farina P; Furini L; Manara R; Dalla Palma M; Rotilio A; Nicoletto O; Zagonel V
Anticancer Res; 2010 Dec; 30(12):5213-6. PubMed ID: 21187515
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Drug Treatments for Glioblastomas.
Ohba S; Hirose Y
Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
10. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
12. Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A; Peters KB
CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
[TBL] [Abstract][Full Text] [Related]
13. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Reardon DA; Turner S; Peters KB; Desjardins A; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Jones LW; Kirkpatrick JP; Friedman AH; Vredenburgh JJ; Bigner DD; Friedman HS
J Natl Compr Canc Netw; 2011 Apr; 9(4):414-27. PubMed ID: 21464146
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for the treatment of glioblastoma.
Chowdhary S; Chamberlain M
Expert Rev Neurother; 2013 Aug; 13(8):937-49. PubMed ID: 23952194
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
16. Is there a Role for Bevacizumab in Non-Glial Tumors?
Trevisan E; Bertero L; Magistrello M; Rudà R; Soffietti R
Curr Drug Targets; 2015; 16(7):684-8. PubMed ID: 25808649
[TBL] [Abstract][Full Text] [Related]
17. RTK inhibition: looking for the right pathways toward a miracle.
Xie Q; Vande Woude GF; Berens ME
Future Oncol; 2012 Nov; 8(11):1397-400. PubMed ID: 23148613
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
[TBL] [Abstract][Full Text] [Related]
19. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
